TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

Submitted by Anonymous on

Professor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong Tong University School of Medicine and principal investigator of the trial, said:" These exciting results from SAFFRON represent a critical advance for patients with EGFR- mutated...

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Submitted by Anonymous on

--BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to...

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

Submitted by Anonymous on

--HUTCHMED Limited today announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS ® plus TAGRISSO ® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doublet platinum-based chemotherapy in...

Computational design and analysis of a lung cancer vaccine targeting EGFR mutation E709G

Submitted by Anonymous on

Non-small cell lung cancer remains a leading cause of cancer-related mortality, driven significantly by specific EGFR mutations. This study utilized a quantum-inspired immunoinformatics framework to design a novel, self-adjuvanted multi-epitope vaccine specifically targeting the atypical EGFR E709G mutation. The computational...

Comparison of healthcare utilization between patients with stage 3–5 CKD and patients with normal-eGFR: an observational study of west region of France

Submitted by Anonymous on

This study aims to compare healthcare utilization between patients with stage 3–5 chronic kidney disease (CKD) and patients with normal estimated glomerular filtration rate (n-eGFR) to identify differences in healthcare needs. This retrospective observational study included patients hospitalized in Western...

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Submitted by Anonymous on

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S....

BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

Submitted by Anonymous on

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that the U.S....

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial

Submitted by Anonymous on

BackgroundAlthough EGFR-TKIs have substantially improved outcomes in EGFR-mutated advanced NSCLC, acquired resistance ultimately leads to treatment failure i Methods and analysisStudy designTrial design This is a single-center, randomized, double-blind, placebo-controlled clinical trial with two parallel groups. A total of 200...

Subscribe to Newsfeed